7 Investor presentation First six months of 2023 International Operations diabete GLP-1 performance Reported Diabetes care sales and growth per IO geography DKK billion Insulin GLP-1 Growth at CER 40 20% 30 62% 20 10 -2% 0 IO Geographical regions 21% 55% -1% EMEA 11% 97% -11% China 27% 58% 9% RoW IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiw Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP- 1 class growth calculated as Ma Source: IQVIA MAT, May 2023 (Spot rate). Volume packs are converted into full-year patients based on WHO assumptions for avera
Download PDF file